On Record: How the FDA Approval of Asymptomatic TAVI Has Changed Practice
Patrick O’Gara and Michael Borger give perspectives from the US and Europe, respectively.
Related Articles
US Stroke Rehab System Not Serving Patient Needs, Societies Say
Access to rehabilitation is a “lifeline” for patients that needs to be protected and preserved to ensure their recovery.
HF Risks Stick Around Even When Ejection Fraction Improves
For the HF patient with a gain in LVEF, there’s little guidance on how best to care for them or manage their GDMT.
AF Patients Could Benefit From Exercise-Based Cardiac Rehab
A new meta-analysis lends support to the idea, but researchers caution many specifics must still be worked out.
Oral GLP-1 Drug Yields 12% Weight Loss in Nondiabetic Patients With Obesity
ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the top dose.
CT-Guided PCI Coming Soon to a Cath Lab Near You—If Not There Already
A joint SCCT/SCAI panel reviewed many opportunities for CT to enhance procedural planning and foster multidisciplinary care.
Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT
In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some areas.
With MISSON Act, Veterans Get More Convenient but Potentially Worse CV Care
While increasing accessibility is “laudable,” it can come at a cost when patients leave the VA for procedures, Jay Giri says.
Eclampsia in Pregnancy Sharply Increases Risk of CVD in the Year After Delivery
The condition, more severe than preeclampsia, should inspire close follow-up for hypertension, heart failure, and stroke.
US Stroke Rehab System Not Serving Patient Needs, Societies Say
Access to rehabilitation is a “lifeline” for patients that needs to be protected and preserved to ensure their recovery.
Oral GLP-1 Drug Yields 12% Weight Loss in Nondiabetic Patients With Obesity
ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the top dose.